Although the immunological therapy of the programmed death 1 (PD-1) immune-checkpoint inhibitors has greatly influenced the treatment of squamous-cell carcinoma of the head and neck, there are some HNSCC patients who benefit from anti–PD-1 antibodies therapy (Chow, 2020). Here, PDCD1 is linked to squamous cell carcinoma.